European Biotechnology Magazine Spring 2021 | Free Excerpt

Interview

ISSN 2364-2351 | A 60711 |

Life Sciences and Industry Magazine Spring Edition 2021 | Volume 20 | 20 €

Caroline Schmutte, Head of the Wellcome Trust’s Berlin Office on global and coordinated action against COVID-19.

T P R E C EE EX

FR

Cultured Meat

Disruption in the dish Vaccine production

Statistics

Bioprocessing

Nationalism in the pandemic might help vaccinate the world

Biotechnology set to play a vital role in the EU’s future economy

COVID-19 powers expanded capacity for gene therapies

Don t prepare. Just be ready.

C2MAP-2000 – 1 method, 17 mins, 95 media components The C2MAP-2000 automates all steps from pretreatment to measurement without any human intervention. It simplifies the workflow for optimizing cell culture conditions. There is no need to prepare. Just be ready.

Complete LCMS solution for cell culture analysis combining the C2MAP-2000 pretreatment module with ultra-fast LCMS-8060

Monitoring of up to 95 components including amino acids, metabolites, sugars, vitamins and organic acids Changes at a glance with C2MAP-TRENDS viewer software visualizing temporal changes of components

Highly efficient through cutting culture media analysis time by 80 percent

www.shimadzu.eu/c2map

C2MAP-2000 – Complete LCMS solution

Intro

European Biotechnology | Spring Edition | Vol. 20 | 2021

FREE EXCERPT

Biotechnology in a post-COVID world – make it so It has been a roller coaster ride for biotechnology since Covid-19 became the virus du jour in early 2020. In a locked-down world with the ongoing human and economic impact, biotechnology has put on its Avengers trousers and roared into action.

Scientists and companies worldwide have advanced novel vaccine development (a rich pipeline of Phase II/III drug candidates) at unprecedented speed, with funders, governments and regulators also breaking records in traditionally very conservative fields.

And biotechnology is not just a pretty face, it is a significant economic contributor. EuropaBio’s recent report ‘The Economic Footprint of the Biotechnology Industry in Europe’ (see p. 10) showed that the biotech industry more than earns its keep and can be clearly positioned at the centre of the EU Industrial Strategy.

Claire Skentelbery, ph.d., a biochemist by training, has worked in the development of scientific associations for 20 years. She started her career within the UK Cambridge biotech cluster and was a co-founder of the Council of European BioRegions. In Brussels from 2009, she was also SG for the European Biotechnology Network, working across sectors, organisations and countries as part of the EBN mission to facilitate partnerships. Claire became DG of the globally-focused Nanotechnology Industries Association until November 2020 when she joined EuropaBio as Director General.

What does this mean for biotechnology in the long term?

The Covid response has broken boundaries and set precedents that we know cannot become the norm for the future, however, it provides lessons and ambitions for biotechnology that enables fast and bigger delivery, whether responding to an urgent crisis like Covid-19 or a world-changing threat like climate change.

Money: Biotech is not cheap, and it is also high-risk – public funders need to be bold and support early-stage R&D for decades often not knowing where it will lead. For Covid, the depth of knowledge enabled new vaccines when we needed them. Europe also needs to enable local private investment at a scale that enables technology delivery, rather than creating a tasty snack for a non-European owner after public money has done its job.

Picture: EuropaBio

Partnerships: A major feature of the Covid-19 experience has been the partnerships that have delivered solutions. Not only the headline partnerships around the vaccines with SMEs, pharma and universities but the immense mobilisation of capabilities across sectors to enable vaccine delivery to patients. Expanding public-private partnerships is the obvious route to take. The EU is ideally placed to drive this and why not act globally? Climate change and pandemics are no respecter of borders.

Politics and regulation: The core instruments of policy, IP and regulation need to be embedded within collaborative platforms so that super-highways to market are a natural extension to the science. Not only does this accelerate the right collaborative science to its destination, it de-risks investment at the scale needed to fuel the journey.

Biotechnology faces a bright future after the darkness of Covid. As a key enabling technology, it has confirmed its place at the heart of Europe’s Industrial Strategy. L

3

Contents

European Biotechnology | Spring Edition | Vol. 20 | 2021

FREE EXCERPT

Cover Story

Insight Europe

Regional News

6

Germany's fast reaction to Coronavirus variants

64 Northern Europe: Sweden, Denmark, Norway and Lithuania

8

Interview: Caroline Schmutte, Head of Berlin Office, Wellcome Trust

66 Western Europe: France, Belgium, The Netherlands and the UK

10 How the biotech industry is

shaping Europe’s economic

footprint

68 Central Europe:

Germany, Switzerland

and Austria

12 Vaccine production in Africa –

an urgent need

70 Southern Europe:

Italy, Spain, Slovenia and Portugal

72 Eastern Europe:

Poland, Hungary and the Czech

Republic

Economy 22 EC launches Beating Cancer plan

14

23 Analyst commentary

Science & Technology

24 Euro Biotech Stocks

73 The end of SARS-CoV-2; Hydrogel heals broken heart; Antidiarrhea drug kills malignancies

Cultured meat arrives

28 IP update: Modernising patent law – boon or bane for patentees?

Factory farming has a devastating impact on the environment, and meat and milk production are responsible for about 15% of the world’s greenhouse gas emissions. Alternative solutions for meeting demand are desperately needed. At the end of 2020, San Francisco-based biotech Eat Just received approval in Singapore to begin selling cultured chicken nuggets in a partnering restaurant. It was the first such approval worldwide – but certain not to be the last. European startups are also looking to scale-up for sales here sooner than you might think.

29 Update on clinical trials 32 Trading medicinal cannabis

in Europe; Peter Homberg;

Dentons LLC, Co-founder

of the ECA 33 Abingworth launches European

life sciences fund 42 Towards BIO-Europe Spring 44 Start-up portrait: Exosome

74 Melting down liver cancer; NASH: Organoids regenerate cholangiocytes; B.1.1.7 more deadly than coronavirus wild type; Researchers map B-cell immunity

Service 75 Associations: News from the SBA 78 EMA News 79 Biopeople 80 Company index/ New products 81 Events 82 Encore

IMPRINT European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: service@european-biotechnology.com, Internet: www.european-biotechnology.com; Publisher: Andreas Mietzsch; Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co-editor), Tobias Thieme; Maren Kühr; Advertising: Oliver Schnell, +49-30-264921-45, Christian Böhm, +49-30-264921-49, Andreas Macht, +49-30-264921-54; Distribution: Lukas Bannert, +49-30-264921-72; Graphic Design: Michaela Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription BIOCOM CARD Europe: €80 for private individuals (students €40) incl. VAT, €120 plus VAT for corporates. Prices includes postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery, which BIOCOM AG is not responsible for, do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Supplement: EuroBiojobsites.com; Cover Photo: somegirl/stock.adobe.com; ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

Picture: Eat Justa

4

Contents

European Biotechnology | Spring Edition | Vol. 20 | 2021

FREE EXCERPT

G7 Meeting

Circular Bioeconomy

Editorial

Passport = freedom?

Global turning point?

Bioprocessing

Ever since the COVID-19 pandemic began forcing lockdowns that cost the state real money, there have been efforts to end one of it's unhappiest measures – social distancing. But the dangers are real. Long-term damage due to infection with SARS-CoV-2 can be immense, and potentially cause occupational disabilities.

As vaccination campaigns pick up steam in Europe, politicians are now reviving an old – and bad – idea: the immunity passport. It's supposed to give vaccinated people more freedom of movement, and deliver on the political promise of a return to an as-yet undefined "normality".

But the concept was already panned by the WHO back in April 2020, and nothing has changed since. There's currently too little evidence that people who have recovered and have antibodies are protected long-term from a second infection, experts say.

Current vaccines do not appear to provide 100% non-contagiousness – one of 12 prerequisites for introducing immunity passports, according to a new "scientific" British study. It also warns that immunity passports could cause envy in the population. It's time for policymakers to finally speak the inconvenient truth. Large-scale experiments on the population are a shaky foundation on which to justify a shortterm return to normalcy. Unfortunately, we still have to wait for more data.

47 Ramping up plasmid production for vaccines and ATMPs 50 Interview: Federico Pollano,

Rentschler Biopharma SE 54 Accelerating study start-up,

Remarque Systems 56 Cooling vaccines, L+R Kältetechnik 58 AAV vectors for SMEs, Biovian 60 Don't bet only on vaccines, Yumab 62 P. pastoris for production, Validogen 63 Europe needs a strategy, BioM

Thomas Gabrielczyk Editor-in-Chief

Over €5.5bn have been committed to vaccinate, diagnose and treat the world's poorest for COVID-19. The Head of the Berlin Office of the Wellcome Trust, Caroline Schmutte, explains why global coordination is crucial for wealthy, industrialised nations as well in the fight against the disease.

34

Bright biotech future

8

Surveys reveal that despite COVID-19, climate change and sustainability continue to matter to consumers – perhaps even more than ever before. The European Commission has proposed investing over €250bn earmarked for its post­-COVID-19 recovery programme into building a sustainable economy. Biotech companies stand to benefit significantly.

Pictures: Pearson 0612/pixabay.com (top), Wellcome Trust (left), Sandoz AG (bottom left)

SPECIAL

5

Rubrik

European Biotechnology | Spring Edition | Vol. 17 | 2018

Biotech premiere in a restaurant in Singapore: the first cultured meat meal is proudly snapped and shared.

Pictures: xxx

14

European Biotechnology | Spring Edition | Vol. 20 | 2021

Cover Story FREE EXCERPT

Biotech disruption in the dish Cultured Meat Factory farming has a devastating impact on the environment, and meat and

milk production are responsible for about 15% of the world’s greenhouse gas emissions. Alternative solutions for meeting demand are desperately needed. At the end of 2020, San Franciscobased biotech Eat Just received approval in Singapore to begin selling cultured chicken nuggets in a partnering restaurant. It was the first such approval worldwide – but certain not to be the last. European start-ups are also looking to scale-up for sales here sooner than you might think.

Picture: Eat Just

I

t was an iconic moment in the debate on climate change. “How dare you!

You have stolen my dreams and my childhood with your empty words.”

Greta Thunberg’s outrage was aimed squarely at world leaders attending the United Nations Climate Action Summit in New York in September of 2019. The activist, who was just 16 at the time, managed to pack an entire generation’s fear and anger into two short sentences. Anger that politicians are doing too little to combat climate change, and fear that it will soon be too late to alter its potentially catastrophic course.

Humanity’s insatiable hunger for meat contributes significantly to anthropogenic climate change. More than 50 giga­tonnes of carbon dioxide and CO2 equivalents were emitted annually by humans in the years before the COVID-19 pandemic.

Around a sixth of them could be traced back to the production of milk and meat, making factory farming one of the major drivers of climate change. Against that backdrop, the Singapore approval in mid-December set a sensational milestone. The US-based start-up Eat Just became the first company in the world to be given a green light to sell a cultured meat product in the city-state.

Figures showing that global food production paradigms must change are overwhelming. According to the Intergovern-

mental Panel on Climate Change (IPCC), the food sector accounts for 21-37% of all greenhouse gas emissions. Data from the Food and Agriculture Organization (FAO) says livestock accounts for about 15% of the total. Almost half comes from the production and processing of animal feed, 39% from enteric fermentation – gases produced in the digestive tracts of ruminants like cattle, sheep and goats – and 10% from storing and processing manure.

“You have stolen my dreams and my childhood with your empty words.”

All told, livestock production accounts for more than half of all emissions subscribed to the food sector. The Heinrich Böll Foundation says 70% of all land used for agricultural purposes globally is employed for livestock production, with around 40% of all arable land used to produce animal fodder.

The non-governmental organisation GRAIN and the Institute for Agriculture and Trade Policy calculated the emissions of 35 of the world’s largest meat and dairy producers back in 2018.

Its study claimed that five major agri­-

corporations – JBS, Tyson, Cargill, the Dairy Farmers of America and Fonterra – together produce more greenhouse gases than any of the major oil multinationals. When their emissions are added up, 20 of the largest food giants produce more greenhouse gases than Germany, the United Kingdom or France. Six such corporations are headquartered in Europe: Arla, Danish Crown, Lactalis, Nestle, FrieslandCampina and Vion.

In its Meat Atlas, the Heinrich Böll Foundation outlines four strategies for reducing emissions, starting with increasing feed and herd productivity, which would mean more meat for a similar environmental impact. Second is the drastic reduction of meat consumption overall.

Then it suggests reducing competition between food and feed production by processing biomass unsuitable for human consumption – such as crop residues – into animal feed. The foundation claims that could reduce emissions by up to 50%. And finally, it recommends reducing carbon footprints through improved animal husbandry methods. It thinks moves like preventing overgrazing through rotating pastures and eliminating the use of grain feed, for example, could cut emissions in half […]

›› Read the full story in the printed issue.

15

Corona-Jab Production

European Biotechnology | Spring Edition | Vol. 20 | 2021

Collaboration is essential to supplying the world with COVID-19 vaccines. The pharma industry, which set records transferring vaccine development to industrial scale production, now stand accused by politicians of lagging behind. But that’s an inaccurate depiction. ‘Slower’ roll-outs in Europe have also been due to strict industry quality controls and organisational challenges at vaccination centres. As EU politicians call loudly for more supplies and faster deliveries, hundreds of thousands of doses of AstraZeneca’s adenovirus vaccine AZD1222 have remained unused in German cold stores. Under massive pressure to meet European demands, the company withdrew supplies from its international production network that are urgently needed in poorer countries where, by the end of February, the first dose had yet to arrive.

Pictures: xxx

34

European Biotechnology | Spring Edition | Vol. 20 | 2021

Vaccine supply FREE EXCERPT

Protecting one mean­s protecting all COVID-19 While developers and producers have put collaboration first in their efforts to meet global

demand for COVID-19 vaccines in record time and win the race against variants, governments continue to prioritise national supplies. But vaccinating many people in just a few countries – and ignoring treatments for those who are already infected – will allow the virus to mutate in other parts of the world.

Companies and political leaders are now under pressure to take some unusual steps.

F

or the head of the Pistoia Alliance, which brings pharma competitors together to tackle intractable problems, the case is clear. “The mindset has to change from ‘we should work together’ to ‘we must work together’ to save lives,” says Steve Arlington. With COVID-19, he adds, “a global pandemic is not over until we have global solutions.”

Picture: Pearson 0612/pixabay.com

Leaders prioritise vaccination When it comes to vaccine production, collaboration efforts between developers, producers and logistic specialists has been tremendous so far, but it’s still not perfect. Biotech companies have kicked off and expanded production networks in record-breaking time – to such an extent that critique from EU politicians about a slow start to vaccine production should soon be a thing of the past.

However, at the end of February, the bloc’s 27 heads of states agreed at an online European Council meeting to further expand pro duc tion capacitie s for COVID-19 vaccines in collaboration with larger producers. They additionally decided to create a new pandemic super­ authority named Hera, and to co-finance and rapidly authorise vaccines that target more contagious variants of SARS-CoV-2 that might soon grow resistant to firstgeneration vaccines. A few days before, the US Food and Drug Administration

(FDA) had published a blueprint on how to speed up emergency authorisation for second-generation COVID-19 vaccines, provided production processes remain the same as those used to make vaccines approved already. The EU’s move came after an initial shortfall in vaccine supply on the continent, particularly streams from BioNTech/Pfizer and AstraZeneca. They provided just 25% and 50% respectively of the vaccine doses they’d committed to produce in the first quarter of 2021.

“Vaccinating many people in a few countries will allow the virus to mutate in large parts of the world. New variants will inevitably spread and come back to us.”

Caroline Schmutte, Wellcome Trust At a simultaneous European Parliament hearing, the CEOs of the six companies with approved or pending COVID-19 vaccines said that initial delays were being caused by challenges in the process transfer of highly complex manufacturing processes to industrial scale, or plant expansions due to growing demand.

As of the end of January, two vaccines from the new class of mRNA jabs made

by BioNTech SE (BNT162b2) and Moder-

na Biotech Inc (mRNA1273) had received conditional EU market authorisation, along with the adenoviral vaccine AZ1222 made

by AstraZeneca plc/University of Oxford (see table p. 36, Fig. p. 38). With the pending approval of Johnson & Johnson’s vector vaccine JNJ-78436735, Novavax’s virus-like protein jab NVX- CoV2373 and Curevac’s mRNA vaccine CVnCOV, which are expected to be greenlighted within the next four months, the perceived bottleneck will widen dramatically.

In fact, by Q4/2021, the European Commission has commitments from these six manufacturers to deliver 2.3 billion doses – enough to immunise every EU citizen 2.8 times over against SARS-CoV-2’s spike protein. The 910 million doses ordered from BioNTech/Pfizer and Moderna Biotech Inc. alone would be enough to vaccinate all EU citizens. In February, German Health Minister Jens Spahn got an extra €6.35bn to purchase additional vaccine doses. In total, Germany has dedicated enough money to buy over 635 million doses, or 7.6 vaccine shots for each of its 83 million citizens.

An inside view from industry “If everyone immediately wants a novel vaccination that they ignored for ten […]

›› Read the full story in the printed issue.

35

product/COmpany Index

European Biotechnology | Spring Edition | Vol. 20 | 2021

FREE EXCERPT

Study COVID-19 variants

Reagents Three fast-spreading new

variants of SARS - CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.

A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain, although the three variants are believed to be independently evolved. These convergent mutations, specifically, the N501Y (shared by all three, 40592-V08H82) and E484K (shared between B.1.351 and P.1, 40592-V08H84), are of high interest because they may be the cause of the increased transmissibility.

The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.

Sino Biological has developed 80+ recombinant RBD/Spike and Nucleocapsid protein mutants carrying the aforementioned mutations, which can be used to evaluate the efficacy of the antibodies and vaccination. 

Contact

Sino Biological Europe GmbH order_eu@sinobiological.com Sino Biological Inc. marketing@sinobiological.com www.sinobiological.com/

AbbVie Ventures (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Abingworth LLP (UK). . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Abliva AB (SE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Accure Therapeutics (ES). . . . . . . . . . . . . . . . . . . . . . . . . . 79 Actelion AG (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Adaptimmune Ltd. (UK). . . . . . . . . . . . . . . . . . . . . . . . . . 66 Advita Lifescience GmbH (DE). . . . . . . . . . . . . . . . . . . . . 69 AgomAB Therapeutics N.V. (BE). . . . . . . . . . . . . . . . . . . . 67 Almirall S. A. (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 AM-Pharma B.V. (NL). . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Amgen Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Apeiron Biologics AG (AT) . . . . . . . . . . . . . . . . . . . . . . . . 68 Aphea.Bio NV (BE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 ArcTern Ventures (CDN). . . . . . . . . . . . . . . . . . . . . . . . . . 18 Arla (SE/DK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Ascendis Pharma A/S (DK). . . . . . . . . . . . . . . . . . . . . . . . 23 AstraZeneca (UK/SE). . . . . . . . . . . . . . . . . . . . . . . . 6, 36, 44 Atsena Therapeutics (USA). . . . . . . . . . . . . . . . . . . . . . . . 33 Augustine Therapeutics (BE). . . . . . . . . . . . . . . . . . . . . . . 67 Autolus Therapeutics Ltd. (UK). . . . . . . . . . . . . . . . . . . . . 66 Bayer AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 BeiGene Co. (CN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 BIA Separations d.o.o. (SLO). . . . . . . . . . . . . . . . . . . . . . . 71 Biftek (TR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Biocheck GmbH (NL). . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 BIOCOM AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . 49, 50 BioInvent International AB (SE). . . . . . . . . . . . . . . . . . . . . 30 BioIVT (US) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 BioM Biotech Cluster Development (DE). . . . . . . . . . . . . . 63 BioNTech SE (DE). . . . . . . . . . . 6, 7, 23, 40, 41, 36, 44 , 69 Biopharma Oryzon Genomics (ES). . . . . . . . . . . . . . . . . . 71 Biotecon GmbH (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 BIOVIAN Oy (FI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49, 58 BlackRock Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Blue Horizon Management AG (CH) . . . . . . . . . . . . . . . . 18 Boehmert & Boehmert (DE) . . . . . . . . . . . . . . . . . . . . 17, 28 Calliditas Therapeutics AB (SE). . . . . . . . . . . . . . . . . . . . . 30 Cellectis SA (FR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Cellink AB (SE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 CellMedica (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Celonic AG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 69 CINO Lexogen GmbH (AT). . . . . . . . . . . . . . . . . . . . . . . . 68 Columbus Venture Partners (ES) . . . . . . . . . . . . . . . . . . . . 71 Confo Therapeutics (BE). . . . . . . . . . . . . . . . . . . . . . . . . . 67 CureVac NV (DE). . . . . . . . . . . . . . . . . . . 23, 29, 36, 41, 69 Cytiva (USA/UK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26–27 Cytovia Therapeutics Inc (USA). . . . . . . . . . . . . . . . . . . . . 65 Danish Crown (DK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Dentons Europe LLP – ECA (GER). . . . . . . . . . . . . . . . . . . 32 Dunn Labortechnik GmbH (DE). . . . . . . . . . . . . . . . . . . . 51 Eat Just (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 EBD Group (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 43 Enthera Pharma (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Eppendorf AG – Bioprocess Center (DE). . . . . . . . . . . . . . 57 ERS Genomcis (IRL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 EuroJobsites Ltd (UK) . . . . . . . . . . . . . . . . . . . . . Supplement European Biotechnology Network (BE). . . . . . . . . . . . 59, 76 EW Group (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Exevir (BE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Exosome Diagnostics GmbH (DE). . . . . . . . . . . . . . . . . . . 44 Faron Pharmaceuticals Ltd. (FI). . . . . . . . . . . . . . . . . . . . . 30 FGK Clinical Research GmbH (DE). . . . . . . . . . . . . . . . . . 29 Fidelta (HR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Fördergesellschaft IZB (DE). . . . . . . . . . . . . . . . . . . . . 31, 44 Fosun Pharma (CN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 FrieslandCampina (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Galapagos NV (BE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Gamaleya Institute (RUS). . . . . . . . . . . . . . . . . . . . . . . . 36, Genentech Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Genmab A/S (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . . 23, 65 Ginolis Oy (FI). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 GlaxoSmithKline (UK) . . . . . . . . . . . . . . . . . . . . . . . . 30, 38 Grupo Blumos (CL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Harter GmbH (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Heidelberg Pharma AG (DE). . . . . . . . . . . . . . . . . . . . . . . 68 HeparRegeniX GmbH (DE). . . . . . . . . . . . . . . . . . . . . . . . 74 Hookipa Biotech AG (AT). . . . . . . . . . . . . . . . . . . . . . 29, 68 Hygiena (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Idorsia (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 IDT Biologika GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . 30 Johnson & Johnson (USA). . . . . . . . . . . . . . . . . . . . . . 36, 44

Just Eat Takeaway.com (NL). . . . . . . . . . . . . . . . . . . . . . . . 18 L&R Kältetechnik GmbH & Co. KG (DE). . . . . . . . . . . 39, 56 Lactalis Group (FR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Lonza AG (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 M Ventures (NL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Marinomed Biotech AG (AT). . . . . . . . . . . . . . . . . . . . . . . 68 Medincell (FR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Merck & Co. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Merck Group/Millipore S.A.S. (GER/F) . . . . . . . . . 12–13, 46 Mina Therapeutics plc (UK) . . . . . . . . . . . . . . . . . . . . . . . 67 Mirai Foods AG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . 18, 20 Moderna Biotech Inc (USA) . . . . . . . . . . . . 6, 29, 36, 40, 44 Mosa Meat (NL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18, 20 Mutabilis SA (FR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Nestle S.A. (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Newron Pharmaceuticals S.p.A. (IT). . . . . . . . . . . . . . . . . 30 NLS Pharmaceutics Ltd (CH). . . . . . . . . . . . . . . . . . . . . . . 68 Northway Biotech (LT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 nova-Institut GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Novameat (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Novartis AG (CH). . . . . . . . . . . . . . . . . . . . . . 23, 41, 47, 69 Novavax Inc. (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Novo Holdings (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Novo Nordisk A/S (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Novozymes A/S (DK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Nutreco (NL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Omnix Medical (IL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Oncopeptides AB (SE). . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Orionis Biosciences (USA). . . . . . . . . . . . . . . . . . . . . . . . 67 Orphan Biovitrum AB (SE) . . . . . . . . . . . . . . . . . . . . . . . . 65 Orphazyme AS (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Oxford Finance LLC (UK). . . . . . . . . . . . . . . . . . . . . . . . . 66 Oxular (UK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Pfizer (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . 6, 7, 36, 40 PharmaMar (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Pharmium Securities (FR). . . . . . . . . . . . . . . . . . . . . . . . . 23 PlasmidFactory GmbH & Co. KG (DE) . . . . . . . . . . . . 41, 48 Precirix (BE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Premier Research (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 11 Protelux (RU). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Redhill Biopharma Ltd (IL) . . . . . . . . . . . . . . . . . . . . . . . . 68 Redx Pharma (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Regeneron Pharmaceuticals Inc. (USA). . . . . . . . . . . . . . . 29 Relief Therapeutics Holding AG (CH). . . . . . . . . . . . . . . . 69 Remarque Systems (USA). . . . . . . . . . . . . . . . . . . . . . . . . 52 Rentschler ATMP Ltd. (UK). . . . . . . . . . . . . . . . . . . . . . . . 66 Rentschler Biopharma (DE). . . . . . . . . . . . . . 29, 48, 66, CP4 Roche AG (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 65 Rubio Impact Ventures (NL) . . . . . . . . . . . . . . . . . . . . . . . 18 Selvita sp. z o.o. (PL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Servier SA (FR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Shimadzu (JP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CP2 Sino Biological Europe GmbH (DE) . . . . . . . . . . . . . . . 9, 80 Sinopharm (CN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 36 Sinovac Life Science (CN). . . . . . . . . . . . . . . . . . . . . . . . . 36 Sofinnova Partners (FR). . . . . . . . . . . . . . . . . . . . . . . . . . . 71 SpyBiotech (UK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Swiss Biotech Association. . . . . . . . . . . . . . . . . . . . . 77, CP3 Synairgen Research plc (UK). . . . . . . . . . . . . . . . . . . . . . . 29 Syndesi Therapeutics (BE). . . . . . . . . . . . . . . . . . . . . . . . . 67 Target Global (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Tigermed Co., Ltd. (CN). . . . . . . . . . . . . . . . . . . . . . . . . . 61 Tilray Portugal Unipressoal Lda (PT). . . . . . . . . . . . . . . . . 71 Tosoh Bioscience (UK). . . . . . . . . . . . . . . . . . . . . . . . 54–55 Transgene SA (FR). . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 79 Tyris Therapeutics (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Unibio International plc (DK). . . . . . . . . . . . . . . . . . . . . . 64 V-Bio Ventures (BE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 VALIDOGEN GmbH (AT). . . . . . . . . . . . . . . . . . . . . . 37, 62 Valneva SE (FR). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 79 Vera Therapeutics (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 33 Vion Food Group (NL) . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Vitro S.A. (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 VivaZome (AUS). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Wacker Chemie AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . 29 West Hill Capital (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Worlpharma Biotech (ES). . . . . . . . . . . . . . . . . . . . . . . . . 71 Yumab GmbH (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 60 Zai Labs (CN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Zealand Pharmaceuticals A/S (DK). . . . . . . . . . . . . . . . . . 23 Zeclinic (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 ZTA Biotech (HUN) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72

Picture: Sino Biological Europe GmbH

80

© Sahachatz/shutterstock.com

New date!

SWISS BIOTECH DAY

7 Sep 2021 Congress Center Basel The Swiss Biotech Day has become the leading biotechnology conference in Europe and is a fixed date in the community’s calendar. While the event could not take place in 2020 due to the worldwide COVID-19 pandemic, we plan to bring the Swiss Biotech Day back on stage on 7 September 2021. We would love to meet you all in person again.

22

... ONE BIOTECH CLUSTER

What you can expect: › Meet senior experts from the life science industry from across Europe › Exhibition throughout the day › Delegations from various regions › Swiss Biotech Success Stories Awards › Innovative biotech start-ups and medium-sized biotech companies › Thematically focused panel discussions › Pre-scheduled one-to-one partnering meetings “WHITE BIOTECHNOLOGY” sector is internationally visible. The project-specific WORKING GROUP

Leading chemical companies are exploring the opportunities that have been opened up by modern biotechnology, especially in the field of “white” or industrial biotechnology. And they are also applying these technologies, wherever it makes sense. The SBA takes such initiatives seriously and has formed a working group specifically dedicated to white biotechnology.

The Swiss Industrial Biocatalysis Consortium is an important partner in this effort. The group includes leading multinational companies that support white Media partners: as a pillar of economic growth. The biotechnology planned activities are in agreement with OECD strategies.

In partnership with the Swiss Biotechnet (see pages 14/15) the SBA develops training programmes and useful support tools for the industry. It is of importance that the industry specifies its training needs so that the academic side can create tailor-made education.

This strategy ensures that the industry gets the right workforce with the right education. The SBA profits

participating companies (most of them young and internationally less savvy) find a comprehensive partner which is helping to put them in the public window.

The participating Life Science Regions are important internal carriers of the dynamics in the Biotech sector, thus enhancing the common understanding of the industry. This and more knowledge is brought into Europa Bio, the European Biotech Association, where the SBA is an active member.

Domenico Alexakis is Executive Director

SWISS BIOTECH...

Sign in on our website at www.swissbiotechday.ch and we will inform you about any news.

...is an alliance of four leading Biotech regions of Switzerland (Bio Alps, BioPolo Ticino, Basel Area and Greater Zurich Area). They have combined efforts to streamline interests of the national biotech sector. The SWX Swiss Exchange holds a leading position in terms of lifescience listings and offers companies from that industry – be they located in Switzerland or abroad – access to an internationally recognised financial marketplace. The initiative was co-founded by the SBA which also manages Organized by: the executive office of Swiss Biotech.

For further information please visit

PASSION FOR PERFORMANCE

YOUR�WORLD-CLASS B I O P H A R M A C E U T I C A L �C D M O •���Experts� in� bioprocess� development� and manufacturing •���Family-owned�company,�globally�thinking�and� focusing�exclusively�on�our�clients‘�projects •���Biopharma� pioneer� with� commitment� to advanced�technology�and�innovation�leadership� •����Extensive� track� record,� over� 40� years� of experience�and�quality�made�in�Germany

YOUR�TRUSTED�PARTNER FROM�CONCEPT�TO�MARKET

BIO-EUROPE�SPRING� DIGITAL MARCH�22-25,�2021 AVAILABLE�ON� DEMAND

Rentschler�Biopharma�SE� Erwin-Rentschler-Str.�21 88471�Laupheim�·�Germany www.rentschler-biopharma.com

Watch�our�Collaboration� Close�up�and�take�a�deep� dive�into�the�partnership� between�Rentschler� Biopharma�and�BioNTech� and�find�out�what�it�took� to�make�this�collaboration� successful.